Are you or someone you know looking to lose weight?
Qualified volunteers may receive at no cost:
-
Investigational medications
-
Study-related medical care from a qualified doctor
-
Possible compensation for time and travel
No health insurance is required to participate in our studies.
View the criteria for each location by clicking the dropdown below, or sign up at the bottom, and our team will contact you directly.
Nature Coast: Inverness – Study (REMAIN 1)
Jacksonville: University Blvd – Study (MARITIME-1)
St. Augustine – Study (MARITIME-ASCVD)
Â
Join a Cardiovascular Health Study for Overweight/Obese Individuals
Qualified participants must/To qualify, you must:
Basic Criteria:
- Be 45 years or older
- Have a BMI of 27 or higher (overweight or obese)
- Have a history of atherosclerotic cardiovascular disease (ASCVD), such as:
- A past heart attack (MI)Â
- A past stroke (ischemic or hemorrhagic)
- Peripheral arterial disease (PAD), shown by symptoms like leg pain when walking, poor circulation, past artery procedures, or an amputation due to blocked arteries
If living with type 2 diabetes (T2DM):
- Diagnosed at least 6 months ago
- Â Have an HbA1c between 6.5% and 10%
- Be on stable treatment with diet, exercise, or certain diabetes medications for at least 90 days before screening
Jacksonville: University Blvd – Obesity with T2DM (A-P)
The purpose of this study is to find out how safe and effective a study treatment is at helping people with overweight or obesity and type 2 diabetes lose weight, compared to a placebo (a treatment with no active medicine).
You may be able to participate if you:
- Have type 2 diabetes
- Have been on the same diabetes treatment for at least 3 months
- Have a BMI of 27 or higher (your provider can help calculate this)
- Have had a stable weight (no more than 5% change) over the past 3 months
Â
You may not be able to participate if any of the following apply to you:
Weight Loss Procedures
- You have had or are planning weight-loss surgery
(Procedures like liposuction or tummy tuck are okay if done more than 1 year ago)
- You have had or are planning medical weight-loss devices or procedures
(Allowed if the device was removed more than 6 months ago)
Medical Conditions
- You have type 1 diabetes
- You have severe heart failure (NYHA Class IV)
- In the past 3 months, you’ve had:
- A heart attack
- A stroke
- A heart procedure (such as stent or bypass)
- Unstable chest pain
- A hospital stay for heart failure
Jacksonville: University Blvd – Obesity with or without T2DM (A-P)
About this study:Â
This study is looking at a treatment to see how well it works and how safe it is for adults who are overweight or have obesity and do not have type 2 diabetes.
The study has two parts:
- Main phase: where participants receive treatment and researchers track things like weight changes and any side effects
- Extension phase: where participants may continue in the study longer so researchers can understand long-term results and safety
You may be able to take part if you:
- Have a BMI of 30 or higher, or27+ with a related health condition (like high blood pressure, high cholesterol, sleep apnea, or heart disease)
- Have had a stable weight (no major changes) over the past 3 months
- Have tried dieting in the past without long-term success
You may not be able to take part if you:
- Have type 1 or type 2 diabetes
- Have had recent serious heart problems (like a heart attack or stroke in the past 3 months)
- Have severe heart failure
- Have had weight-loss procedures or devices recently
- Have used weight-loss medications in the past 3 months
Why participate?
- Help advance research in heart disease prevention
- Compensation may be available (if applicable)
Study Details:Â
Location: Jacksonville, FLÂ
All study- related care is provided at no cost to you or your insurance company.
Jacksonville: University Blvd – AMAZE 7 Obesity-COMING SOON!
NOVO-NN9490-8027 AMAZE 7 Obesity
About this Study:
The purpose of this study is to find out if zenagamtide is safe and effective for treating participants who have excess body weight compared to treatment with semaglutide.
Inclusion Criteria:
- Body mass index (BMI) at screening ≥ 30.0 kg/m2.
- Previous or planned (during the study period) obesity treatment with surgery or a weight loss device. However, the following are allowed:
- Liposuction and/or abdominoplasty, if performed > 1 year before screening
- Adjustable gastric banding, if the band has been removed > 1 year before screening
- Intragastric balloon, if the balloon has been removed > 1 year before screening
- Duodenal-jejunal bypass liner (e.g. Endobarrier), if the sleeve has been removed > 1 year before screening
- Non-pharmaceutical, non-invasive, biodegradable devices, if last used > 1 year before screening
Exclusion Criteria:
- Glycated haemoglobin (HbA1c) ≥ 6.5% (48 millimoles per mole [mmol/mol]) as measured by the central laboratory at screening.
- History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records.
- Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues within 1 year before screening.
Why participate?
- Help advance research in heart disease prevention
- Compensation may be available (if applicable)
Study Details:Â
Location: Jacksonville, FLÂ
All study- related care is provided at no cost to you or your insurance company.
This research is enrolling at:
Read the latest posts by our expert clinical staff!
